Clinical Trials - February 18, 2016
AZ’s Durvalumab granted Breakthrough Therapy designation
AstraZeneca and MedImmune, have announced that the US Food and Drug Administration has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based […]
Drug Development Pharma - February 13, 2016
AZ’s Zurampic approved in the EU for patients with gout
AstraZeneca has announced that the European Commission has granted marketing authorisation for ZurampicTM (lesinurad) 200mg in combination with a xanthine oxidase inhibitor (XOI) for the adjunctive treatment of hyperuricemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid (sUA) levels with an adequate dose of an XOI alone. Zurampic […]
Collaboration - February 9, 2016
Allergan and AstraZeneca collaborate
Allergan has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. Together, the two companies will evaluate the combination to treat serious infections caused by metallo βlactamase MBL-producing Gram-negative pathogens, a difficult-to-treat sub-type of carbapenem-resistant Enterobacteriaceae (CRE), for which there are currently very limited […]
Drug Development Pharma - February 3, 2016
AZ granted market authorisation for TAGRISSO
The European Commission has granted conditional marketing authorisation for AstraZeneca’s TAGRISSO, 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). Osimertinib is indicated for patients with T790M mutation-positive NSCLC, irrespective of previous treatment with an EGFR tyrosine kinase […]
Funding - January 26, 2016
AstraZeneca establish translational research fund
AstraZeneca together with GlaxoSmithKline and Johnson & Johnson has partnered with three universities, Imperial College London, the University of Cambridge and University College London (UCL), to create the Apollo Therapeutics Fund. This new consortium aims to convert outstanding academic science from the three universities into innovative medicines for a broad range of diseases. The fund […]
Collaboration - January 13, 2016
AstraZeneca enters two new collaborations
AstraZeneca announce a new collaboration with Moderna Therapeutics to co-develop and co-commercialise immuno-oncology mRNA therapeutics and a new lung cancer clinical trial collaboration with Incyte. Lung cancer clinical trial collaboration The collaboration with Incyte aims to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s epidermal growth factor receptor (EGFR) […]
